Sugi Predict

Sugi Predict / Compounds / SCHEMBL30686152

SCHEMBL30686152

SCHEMBL30686152

O=C(N[C@@H](CCc1ccc(Cl)c(C(F)(F)F)c1)C(=O)O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 7/20 0.49
▸ MMP7 P09237 1/20 0.48
▸ MDM4 O15151 3/20 0.46
▸ TP53 P04637 3/20 0.46
▸ TLR2 O60603 2/20 0.43
▸ CASP3 P42574 1/20 0.42
▸ SLC17A5 Q9NRA2 1/20 0.41
▸ TNF P01375 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29277322 1.00 MDM2 (0.49) MDM2MMP7MDM4TP53TLR2
SCHEMBL29277324 1.00 MDM2 (0.49) MDM2MMP7MDM4TP53TLR2
SCHEMBL22454854 0.93 MDM2 (0.49) MDM2MMP7MDM4TP53TLR2
SCHEMBL29709620 0.93 MDM2 (0.49) MDM2MMP7MDM4TP53TLR2
SCHEMBL22444643 0.93 MDM2 (0.49) MDM2MMP7MDM4TP53TLR2
SCHEMBL31072743 0.93 MDM2 (0.49) MDM2MMP7MDM4TP53TLR2
SCHEMBL31370377 0.92 MDM2 (0.51) MDM2MDM4TP53TLR2CASP3
SCHEMBL25186431 0.89 MDM4 (0.50) MDM2MDM4TP53TLR2CASP3
SCHEMBL30889919 0.89 MDM4 (0.50) MDM2MDM4TP53TLR2CASP3
SCHEMBL30510253 0.89 MDM4 (0.50) MDM2MDM4TP53TLR2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-07-17 — — US disclosed
CN-120202211-A Cyclic compounds having selective KRAS inhibition over HRAS and NRAS 中外制药株式会社 2025-06-24 — — CN disclosed
CN-119731195-A Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS 中外制药株式会社 2025-03-28 — — CN disclosed
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-13 — — US disclosed
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-16 — — US disclosed
CN-117279933-A Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS 中外制药株式会社 2023-12-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS KRAS, HRAS, NRAS MDM2 47/4885MMP7 3702/4885MDM4 476/4885
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS KRAS, HRAS, NRAS MDM2 30/4885MMP7 4381/4885MDM4 455/4885
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS MDM2 30/4885MMP7 4381/4885MDM4 455/4885
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS MDM2 30/4885MMP7 4381/4885MDM4 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.